For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Haemonetics Corp’s stock clocked out at $64.57, down -0.55% from its previous closing price of $64.93. In other words, the price has decreased by -$0.55 from its previous closing price. On the day, 1.02 million shares were traded.
Ratios:
To gain a deeper understanding of HAE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.81. For the most recent quarter (mrq), Quick Ratio is recorded 2.55 and its Current Ratio is at 3.97. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 1.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on February 07, 2025, Downgraded its rating to Underperform and sets its target price to $68 from $95 previously.
On December 06, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $116.
Raymond James Upgraded its Outperform to Strong Buy on November 08, 2024, while the target price for the stock was maintained at $120.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Lingamneni Anila bought 6,238 shares for $90.68 per share.
Strong Stewart W sold 4,312 shares of HAE for $393,039 on Jul 26 ’24. The President, Global Hospital now owns 18,196 shares after completing the transaction at $91.15 per share. On Jul 26 ’24, another insider, Strong Stewart W, who serves as the Officer of the company, bought 4,312 shares for $91.15 each.
Valuation Measures:
As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.41, and their Forward P/E ratio for the next fiscal year is 12.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.36 while its Price-to-Book (P/B) ratio in mrq is 3.58.
Stock Price History:
Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $58.80. The 50-Day Moving Average of the stock is -9.93%, while the 200-Day Moving Average is calculated to be -19.04%.
Shares Statistics:
A total of 50.24M shares are outstanding, with a floating share count of 49.68M. Insiders hold about 1.11% of the company’s shares, while institutions hold 113.61% stake in the company.
